Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nano-SMART
NCT04789486Phase 2Recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2021
- Primary completion
- Apr 2028
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of AGuIX in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), sponsored by Dana-Farber Cancer Institute. Started May 2021; status: recruiting.
02
Drugs
AGuIX
03
Conditions
non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04789486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789486.